SLC5A2 and type 2 diabetes mellitus: Along with sodium-glucose cotransporter 2 (SGLT2) inhibitors, GLP-1RAs have become the first-line therapy for T2DM due to their potent glucose-lowering effects and their ability to reduce the cardiovascular risk irrespective of the glycemic improvement or the weight loss [23].